Interestingly, inhibition of C1 leads to the metabolic consequences typical of PPAR ligands pharmacological activities (hypolipidemic and hypoglycemic effects) [19,20] and this could, in turn, explain some of their toxic effects (rabdomyolisis, acute liver failure) already widely reported [14,15,16,17,18,19,20,21,22,23]. This evidence concerns the gene PPARA and acute liver failure.